STAT March 15, 2024
Meghana Keshavan

Hey there. Today, we see the first approval of a drug to treat MASH, a Gilead medication shows huge promise in Ebola, and more.

The need-to-know this morning

  • Bristol Myers Squibb won FDA approval to expand the use of its Breyanzi CAR-T treatment to include patients with chronic lymphocytic leukemia. Breyanzi, already approved for lymphoma, is the first personalized cell therapy to receive an additional regulatory clearance to treat this type of blood cancer.

Madrigal wins first approval for MASH drug

The FDA yesterday granted an accelerated approval for the first medicine to treat MASH. The pill, made by Madrigal Pharmaceuticals, is called Rezdiffra. MASH is a serious liver disease that is linked to obesity and causes inflammation...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
How will CMS administer the IRA Medicare Drug Price Negotiation under Trump?
STAT+: How Trump’s tariffs may raise health care costs, from medical devices to prescription drugs
One Institution’s Evidence-Based Approach to Adopting Biosimilars

Share This Article